AI vs. cancer: AstraZeneca exec reveals how COVID pandemic helped develop early cancer diagnosis tech

AstraZeneca's Dave Fredrickson discusses how the COVID-19 pandemic helped to bolster early cancer diagnosis from lung scans. AstraZeneca is pushing forward with implementing artificial intelligence (AI) in early cancer diagnosis and drug treatment plans with the hope of significantly reducing mortality rates over the next two decades. David Fredrickson, the Executive Vice-President of the company's Oncology Business Unit, recently expressed his hope for the future of oncological work at the Milken Institute Global Conference, detailing what he expects cancer outlooks might look like in the year 2040. Speaking with Fox News Digital, Fredrickson said he expects blood-based screening to allow healthcare providers to identify cancer as early as possible and with the greatest potential for finding a cure. The rapid acceleration of AI technology could also help to pair a medicine or a combination of medicines with a specific signature that a patient has for why their cancer is growing inside them.